BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29571993)

  • 21. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
    Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
    Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
    Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
    Reboul FL
    Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent chemoradiotherapy in non-small cell lung cancer.
    Rowell NP; O'rourke NP
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002140. PubMed ID: 15495029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).
    Schild SE; Hillman SL; Tan AD; Ross HJ; McGinnis WL; Garces YA; Graham DL; Adjei AA; Jett JR;
    J Thorac Oncol; 2017 Apr; 12(4):697-703. PubMed ID: 28089762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
    Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
    J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
    Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage III non-small-cell lung cancer.
    Zhao H; Zhu W; Xie P; Li H; Zhang X; Sun X; Yu J; Xing L
    Radiother Oncol; 2014 Jan; 110(1):132-6. PubMed ID: 24444526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre.
    Spencer A; Williams J; Samuel R; Boon IS; Clarke K; Jain P
    Cancer Treat Res Commun; 2021; 29():100460. PubMed ID: 34598059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
    Zwitter M; Kovac V; Smrdel U; Strojan P
    J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Induction chemotherapy followed by concomitant combined radiotherapy and chemotherapy in stage III non-small cell bronchial carcinoma].
    Bouillet T; Morère JF; Mazeron JJ; Piperno-Neuman S; Boaziz C; Haddad E; Breau JL
    Cancer Radiother; 1997; 1(2):121-31. PubMed ID: 9273182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.
    Bao Y; Peng F; Zhou QC; Yu ZH; Li JC; Cheng ZB; Chen L; Hu X; Chen YY; Wang J; Wang Y; Ma HL; Xu ZM; Lu RB; Deng XW; Chen M
    Radiother Oncol; 2015 Feb; 114(2):161-6. PubMed ID: 25497558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer.
    Zhu ZF; Ma HL; Fan M; Bao Y; Zhuang TT; Chen M; Jiang GL; Fu XL
    Technol Cancer Res Treat; 2014 Jun; 13(3):269-75. PubMed ID: 24066952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent chemoradiotherapy in non-small cell lung cancer.
    O'Rourke N; Roqué I Figuls M; Farré Bernadó N; Macbeth F
    Cochrane Database Syst Rev; 2010 Jun; (6):CD002140. PubMed ID: 20556756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
    Socinski MA; Morris DE; Halle JS; Moore DT; Hensing TA; Limentani SA; Fraser R; Tynan M; Mears A; Rivera MP; Detterbeck FC; Rosenman JG
    J Clin Oncol; 2004 Nov; 22(21):4341-50. PubMed ID: 15514375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
    Faivre-Finn C; Snee M; Ashcroft L; Appel W; Barlesi F; Bhatnagar A; Bezjak A; Cardenal F; Fournel P; Harden S; Le Pechoux C; McMenemin R; Mohammed N; O'Brien M; Pantarotto J; Surmont V; Van Meerbeeck JP; Woll PJ; Lorigan P; Blackhall F;
    Lancet Oncol; 2017 Aug; 18(8):1116-1125. PubMed ID: 28642008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
    Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
    Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable).
    Rowell NP; Williams CJ
    Cochrane Database Syst Rev; 2001; (2):CD002935. PubMed ID: 11406051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.